Angiotensin inhibition in renovascular disease: A population-based cohort study

American Heart Journal

Volumn 156, Issue 3, 2008, Pages 549-555

  Hackam, Daniel G ^a   Duong Hua, Minh L ^b   Mamdani, Muhammad ^b,c   Li, Ping ^b   Tobe, Sheldon W ^d   Spence, J David ^a   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIALYSIS; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; RISK ASSESSMENT; STROKE;

AGED; AGED, 80 AND OVER; ANGIOTENSINS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HORMONE ANTAGONISTS; HOSPITALIZATION; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, ACUTE; MALE; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; STROKE; VASCULAR DISEASES;

EID: 49949116692     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.05.013     Document Type: Article

References (57)

1. Hansen K.J., Edwards M.S., et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg 36 (2002) 443-451
2. Guo H., Kalra P.A., et al. Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001. Circulation 115 (2007) 50-58
3. Knipp B.S., Dimick J.B., et al. Diffusion of new technology for the treatment of renovascular hypertension in the United States: surgical revascularization versus catheter-based therapy, 1988-2001. J Vasc Surg 40 (2004) 717-723
4. Fatica R.A., Port F.K., et al. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 37 (2001) 1184-1190
5. Kalra P.A., Guo H., et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 68 (2005) 293-301
6. Main J. Atherosclerotic renal artery stenosis, ACE inhibitors, and avoiding cardiovascular death. Heart 91 (2005) 548-552
7. Spence J.D. Treatment options for renovascular hypertension. Expert Opin Pharmacother 3 (2002) 411-416
8. Yang J.G., Hu D., et al. Angiotensin-converting enzyme inhibitor usage in patients with incidental atherosclerotic renal artery stenosis. Hypertension Research-Clinical & Experimental 27 (2004) 339-344
9. Hackam D.G., Spence J.D., et al. The role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension 50 (2007) 998-1003
10. Kumar A., Asim M., et al. Taking precautions with ACE inhibitors. A theoretical risk exists in patients with unilateral renal artery stenosis. BMJ 316 (1998) 1921
11. Onuigbo M.A., and Onuigbo N.T. Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience. Med Sci Monit 11 (2005) CR462-CR469
12. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol 12 (1996) 127-137
13. Gomma A.H., and Fox K.M. The EUROPA Trial: design, baseline demography and status of the substudies. Cardiovascular Drugs and Therapy 15 (2001) 169-179
14. Pfeffer M.A., Domanski M., et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Am J Cardiol 82 (1998) 25-30
15. Des Jarlais D.C., Lyles C., et al. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 94 (2004) 361-366
16. von E.E., Altman D.G., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147 (2007) 573-577
17. Levy A.R., O'Brien B.J., et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10 (2003) 67-71
18. Austin P.C., Daly P.A., et al. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 144 (2002) 290-296
19. Lindsay M.P., Kapral M.K., et al. Validation of administrative databases using a registry data source: implications for research on quality of stroke care. Stroke 36 (2005) 477
20. Technical methods-Appendix 1. In: Naylor C.D., and Slaughter P.M. (Eds). Cardiovascular health and services in Ontario: an ICES Atlas (1999), Institute for Clinical Evaluative Sciences
21. Lee D.S., Donovan L., et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 43 (2005) 182-188
22. Juurlink D., Preyra C., Croxford R., et al. Canadian Institute for Health Information Discharge Abstract Database: a validation study (2006), Institute for Clinical Evaluative Sciences, Toronto
23. Richards J., Brown A., and Homan C. The data quality study of the Canadian discharge abstract database. Achieving data quality in a statistical agency: a methodological perspective. Proceedings of Statistics Canada Symposium Issue 2001. Statistics Canada, Ottawa, Ontario, Canada (2001)
24. Data quality of the discharge abstract database following the first-year implementation of ICD-10-CA/CCI: final report (2004), Canadian Institute for Health Information, Ottawa, Ontario, Canada
25. Cox J.L., Melady M.P., et al. Towards improved coding of acute myocardial infarction in hospital discharge abstracts: a pilot project. Can J Cardiol 13 (1997) 351-358
26. Jong P., Gong Y., et al. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation 108 (2003) 184-191
27. Safian R.D., and Textor S.C. Renal artery stenosis. N Engl J Med 344 (2001) 431-442
28. Edwards M.S., Craven T.E., et al. Renovascular disease and the risk of adverse coronary events in the elderly: a prospective, population-based study. Arch Intern Med 165 (2005) 207-213
29. Mui K.W., Sleeswijk M., et al. Incidental renal artery stenosis is an independent predictor of mortality in patients with peripheral vascular disease. J Am Soc Nephrol 17 (2006) 2069-2074
30. Edwards M.S., Hansen K.J., et al. Associations between renovascular disease and prevalent cardiovascular disease in the elderly: a population-based study. Vasc Endovascular Surg 38 (2004) 25-35
31. Uzu T., Takeji M., et al. Prevalence and outcome of renal artery stenosis in atherosclerotic patients with renal dysfunction. Hypertens Res 25 (2002) 537-542
32. Pillay W.R., Kan Y.M., et al. Prospective multicentre study of the natural history of atherosclerotic renal artery stenosis in patients with peripheral vascular disease. Br J Surg 89 (2002) 737-740
33. Cheung C.M., Wright J.R., et al. Epidemiology of renal dysfunction and patient outcome in atherosclerotic renal artery occlusion. J Am Soc Nephrol 13 (2002) 149-157
34. Conlon P.J., Little M.A., et al. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int 60 (2001) 1490-1497
35. Bates M.C., Campbell J.E., et al. Factors affecting long-term survival following renal artery stenting. Catheter Cardiovasc Interv 69 (2007) 1037-1043
36. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16 (2007) 241-249
37. Alfonzo A.V., Isles C., et al. Potassium disorders-clinical spectrum and emergency management. Resuscitation 70 (2006) 10-25
38. Devoy M.A., Tomson C.R., et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 232 (1992) 493-498
39. Johansen T., and Kjaer A. Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrology 2 (2001) 1
40. Kothari S.S. ACE inhibitors and unilateral renal artery stenosis-what price?. Int J Cardiol 53 (1996) 199-201
41. Kindler J., Konrads A., et al. Progressive reversible kidney insufficiency after blood pressure reduction with captopril. Internist (Berl) 22 (1981) 360-363
42. Collste P., Haglund K., et al. Reversible renal failure during treatment with captopril. Br Med J 2 (1979) 612-613
43. Cooper C.J., Murphy T.P., et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J 152 (2006) 59-66
44. Tullis M.J., Caps M.T., et al. Blood pressure, antihypertensive medication, and atherosclerotic renal artery stenosis. Am J Kidney Dis 33 (1999) 675-681
45. Franklin S.S., and Smith R.D. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 79 (1985) 14-23
46. Hodsman G.P., Brown J.J., et al. Enalapril (MK421) in the treatment of hypertension with renal artery stenosis. J Hypertens Suppl 1 (1983) 109-117
47. Ogihara T., Kaneko Y., et al. Clinical evaluation of delapril in Japan. Report from the Japan Study Group on Delapril. Am J Hypertens 4 (1991) 42S-45S
48. Reams G.P., and Bauer J.H. Enalapril versus triple-drug therapy in the treatment of renovascular hypertension. Drugs 30 Suppl 1 (1985) 59-69
49. Schwietzer G., and Oelkers W. The antihypertensive effect of captopril in severe essential, renovascular, renal and transplant renovascular hypertension. Klin Wochenschr 60 (1982) 839-846
50. Papanikolaou P.N., Christidi G.D., et al. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 174 (2006) 635-641
51. Casas J.P., Chua W., et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
52. Strippoli G.F., Craig M., et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329 (2004) 828
53. Jafar T.H., Stark P.C., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139 (2003) 244-252
54. Siebenhofer A., Plank J., et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabet Med 21 (2004) 18-25
55. Rucinska E.J., Small R., et al. High-risk patients treated with enalapril maleate: safety considerations. Int J Cardiol 22 (1989) 249-259
56. van de Ven P.J., Beutler J.J., et al. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 53 (1998) 986-993
57. Jackson B., Matthews P.G., et al. Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure. Lancet 1 (1984) 225-226